Abstract:Background: Targeted therapy for lung cancer with epidermal growth factor receptor (EGFR) mutations with tyrosine kinase inhibitors (TKIs) represents one of the major breakthroughs in lung cancer management. However, gradually developed resistance to these drugs prevents sustained clinical benefits and calls for resistant mechanism research and identification of new therapeutic targets. Acquired T790M mutation accounts for the majority of resistance cases, yet transcriptome changes in these cells are less characterized, and it is not known if new treatment targets exist by available drugs. Methods: Transcriptome profiling was performed for lung cancer cell line PC9 and its resistant line PC9GR after long-term exposure to gefitinib through RNA sequencing. Differentially expressed genes and changed pathways were identified along with existing drugs targeting these upregulated genes. Using 144 lung cancer cell lines with both gene expression and drug response data from the cancer cell line encyclopedia (CCLE) and Cancer Therapeutics Response Portal (CTRP), we screened 549 drugs whose response was correlated with these upregulated genes in PC9GR cells, and top drugs were evaluated for their response in both PC9 and PC9GR cells. Results: In addition to the acquired T790M mutation, the resistant PC9GR cells had very different transcription programs from the sensitive PC9 cells. Multiple pathways were changed with the top ones including TNFA signaling, androgen/estrogen response, P53 pathway, MTORC1 signaling, hypoxia, and epithelial mesenchymal transition. Thirty-two upregulated genes had available drugs that can potentially be effective in treating the resistant cells. From the response profiles of CCLE, we found 17 drugs whose responses were associated with at least four of these upregulated genes. Among the four drugs evaluated (dasatinib, KPT-185, trametinib, and pluripotin), all except trametinib demonstrated strong inhibitory effects on the resistant PC9GR cells, among which KPT185 was the most potent. KPT-185 suppressed growth, caused apoptosis, and inhibited migration of the PC9GR cells at similar (or better) rates as the sensitive PC9 cells in a dose-dependent manner. Conclusions: Acquired TKI-resistant lung cancer cells (PC9GR) have dramatically changed transcription and pathway regulation, which expose new treatment targets. Existing drugs may be repurposed to treat those patients with developed resistance to TKIs.

ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC

Drug Resistance Mechanism of Non Small Cell Lung Cancer PC9/AB2 Cell Line with Acquired Drug Resistance to Gefitinib

Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.

Beta 1 Integrin Mediated Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Lung Cancer Cells

Lnc-ABCA12-8 Confers Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer by Regulating the Alternative Splicing of Fibronectin 1 in the IIICS Region

Β-Catenin Overexpression is Associated with Gefitinib Resistance in Non-Small Cell Lung Cancer Cells.

Integrin Β1 Participates in Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer

[Sensitivity of Two Cell Lines with Acquired Resistance to Gefitinib to Several Chemotherapeutic Drugs].

The Epidermal Growth Factor Tyrosine Kinase Inhibitor Ag1478 and Erlotinib Reverse Abcg2-Mediated Drug Resistance

Gefitinib Reverses Chemotherapy Resistance In Gefitinib-Insensitive Multidrug Resistant Cancer Cells Expressing Atp-Binding Cassette Family Protein

Role of ABCA2 and its single nucleotide polymorphisms (4873T>A and 4879G>C) in the regulation of multi-drug resistance in oral squamous carcinoma cells

An Integrative Analysis of the Putative Gefitinib-resistance Related Genes in a Lung Cancer Cell Line Model System

DDX17 Nucleocytoplasmic Shuttling Promotes Acquired Gefitinib Resistance in Non-Small Cell Lung Cancer Cells Via Activation of Β-Catenin.

Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs

Genome-wide Identification and Characterization of Long Non-Coding RNAs Involved in Acquired Resistance to Gefitinib in Non-Small-cell Lung Cancer

Identification of Hub Genes and Small Molecule Drugs Associated with Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer

LY2874455 and Abemaciclib Reverse FGF3/4/19/CCND1 Amplification Mediated Gefitinib Resistance in NSCLC

Integrative Analysis of Proteome and Ubiquitylome Reveals Unique Features of Lysosomal and Endocytic Pathways in Gefitinib-Resistant Non-Small Cell Lung Cancer Cells.

Original Overexpression of ABCB1 Confers Resistance to FLT3 Inhibitor FN-1501 in Cancer Cells: in Vitro and in Vivo Characterization

Transcriptome Profiling of Acquired Gefitinib Resistant Lung Cancer Cells Reveals Dramatically Changed Transcription Programs and New Treatment Targets.

Erlotinib (tarceva, OSI-774) Antagonizes ATP-binding Cassette Subfamily B Member 1 and ATP-binding Cassette Subfamily G Member 2-Mediated Drug Resistance.